AR086451A1 - Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto - Google Patents

Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto

Info

Publication number
AR086451A1
AR086451A1 ARP120101766A ARP120101766A AR086451A1 AR 086451 A1 AR086451 A1 AR 086451A1 AR P120101766 A ARP120101766 A AR P120101766A AR P120101766 A ARP120101766 A AR P120101766A AR 086451 A1 AR086451 A1 AR 086451A1
Authority
AR
Argentina
Prior art keywords
group
cycloalkyl
hydrogen atom
atom
optionally substituted
Prior art date
Application number
ARP120101766A
Other languages
English (en)
Inventor
Franz Lorge
Valerie Martin
Gilbert Lassalle
Olivier Duclos
Alain Braun
Olaf Ritzeler
Aurelie Strub
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44247865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR086451A1 publication Critical patent/AR086451A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la presente son útiles en el tratamiento de la linfoangiogénesis, inflamación crónica o no crónica artritis reumatoide y enfermedad de Gorham.Reivindicación 1: Compuesto que corresponde a la fórmula (1), en la que: W representa un átomo de nitrógeno o un grupo CH; Y representa un grupo alquinileno C2-3, un 1,4-fenileno opcionalmente sustituido con R7, que representa uno o más átomo(s) de halógeno; Z representa un enlace o un grupo CR1R2; R1 y R2, independientemente uno de otro, representan un grupo seleccionado de un átomo de hidrógeno, un grupo alquilo C1-6, un grupo trifluorometilo, un grupo (CH2)nOR6, cicloalquilo C3-7, un heteroarilo o un arilo opcionalmente sustituido con uno o más átomo(s) de halógeno; R1 y R2 pueden formar juntos, con el átomo de carbono al que están unidos, un cicloalquilo C3-7; R3 representa un átomo de hidrógeno; R4 representa un grupo seleccionado de un grupo alquilo C1-6, un grupo (CH2)nOR6, cicloalquilo C3-7 o alquilo C1-6 opcionalmente sustituido por un cicloalquilo C3-7; R5 representa un grupo seleccionado de un átomo de hidrógeno o un grupo alquilo C1-6; R6 representa un grupo seleccionado de un átomo de hidrógeno o un grupo alquilo C1-6; n es igual a 1, 2 ó 3; en la forma de la base o de una sal de adición de ácido.
ARP120101766A 2011-05-20 2012-05-18 Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto AR086451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305624A EP2524915A1 (en) 2011-05-20 2011-05-20 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
AR086451A1 true AR086451A1 (es) 2013-12-11

Family

ID=44247865

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101766A AR086451A1 (es) 2011-05-20 2012-05-18 Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto

Country Status (35)

Country Link
US (2) US9126972B2 (es)
EP (2) EP2524915A1 (es)
JP (1) JP5937201B2 (es)
KR (1) KR102005121B1 (es)
CN (1) CN103687852B (es)
AR (1) AR086451A1 (es)
AU (1) AU2012261077B2 (es)
BR (1) BR112013029820B1 (es)
CA (1) CA2833192C (es)
CL (1) CL2013003091A1 (es)
CO (1) CO6811857A2 (es)
CR (1) CR20130541A (es)
CY (1) CY1116720T1 (es)
DK (1) DK2709996T3 (es)
DO (1) DOP2013000241A (es)
EA (1) EA023580B1 (es)
EC (1) ECSP13013016A (es)
ES (1) ES2548266T3 (es)
GT (1) GT201300250A (es)
HR (1) HRP20150974T1 (es)
HU (1) HUE025111T2 (es)
IL (1) IL229210A0 (es)
MA (1) MA35196B1 (es)
MX (1) MX348842B (es)
NI (1) NI201300125A (es)
PE (1) PE20141527A1 (es)
PL (1) PL2709996T3 (es)
PT (1) PT2709996E (es)
SG (1) SG194204A1 (es)
SI (1) SI2709996T1 (es)
TN (1) TN2013000420A1 (es)
TW (1) TWI532740B (es)
UA (1) UA109942C2 (es)
UY (1) UY34082A (es)
WO (1) WO2012159959A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
PT2874625T (pt) * 2012-07-17 2017-08-16 Sanofi Sa Uso de inibidores vegfr-3 para tratar carcinoma hepatocelular
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CA3089657A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN114502555B (zh) * 2019-10-15 2024-07-16 常州千红生化制药股份有限公司 用于治疗增殖性疾病和疾患的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶-3-基)嘧啶-2-胺的衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3-位取代的喹诺酮衍生物及其在药学上的应用
CA2543820C (en) * 2003-11-07 2012-07-10 Chiron Corporation Methods for synthesizing quinolinone compounds
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
US20100144751A1 (en) 2007-03-28 2010-06-10 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
FR2917412B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
PT2874625T (pt) * 2012-07-17 2017-08-16 Sanofi Sa Uso de inibidores vegfr-3 para tratar carcinoma hepatocelular

Also Published As

Publication number Publication date
CR20130541A (es) 2013-12-09
US9675606B2 (en) 2017-06-13
UY34082A (es) 2013-01-03
MA35196B1 (fr) 2014-06-02
MX348842B (es) 2017-06-30
BR112013029820B1 (pt) 2020-02-04
EA201391744A1 (ru) 2014-03-31
CN103687852A (zh) 2014-03-26
DK2709996T3 (en) 2015-09-28
PE20141527A1 (es) 2014-11-08
KR20140025465A (ko) 2014-03-04
CL2013003091A1 (es) 2014-04-04
US20150328205A1 (en) 2015-11-19
BR112013029820A2 (pt) 2016-12-06
EP2709996B1 (en) 2015-06-24
PT2709996E (pt) 2015-10-16
CA2833192C (en) 2019-10-22
IL229210A0 (en) 2014-01-30
PL2709996T3 (pl) 2015-12-31
DOP2013000241A (es) 2013-12-31
CN103687852B (zh) 2016-08-17
NZ617931A (en) 2015-05-29
UA109942C2 (ru) 2015-10-26
JP5937201B2 (ja) 2016-06-22
AU2012261077B2 (en) 2016-05-05
GT201300250A (es) 2015-03-05
TWI532740B (zh) 2016-05-11
MX2013013572A (es) 2014-01-16
CO6811857A2 (es) 2013-12-16
CA2833192A1 (en) 2012-11-29
ECSP13013016A (es) 2013-12-31
HRP20150974T1 (en) 2015-10-09
JP2014513707A (ja) 2014-06-05
TN2013000420A1 (en) 2015-03-30
EP2709996A1 (en) 2014-03-26
TW201300386A (zh) 2013-01-01
SG194204A1 (en) 2013-12-30
US9126972B2 (en) 2015-09-08
SI2709996T1 (sl) 2015-10-30
US20140094488A1 (en) 2014-04-03
AU2012261077A1 (en) 2013-12-12
EA023580B1 (ru) 2016-06-30
KR102005121B1 (ko) 2019-07-29
ES2548266T3 (es) 2015-10-15
HUE025111T2 (en) 2016-02-29
EP2524915A1 (en) 2012-11-21
WO2012159959A1 (en) 2012-11-29
CY1116720T1 (el) 2017-03-15
NI201300125A (es) 2014-02-20

Similar Documents

Publication Publication Date Title
AR086451A1 (es) Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto
PE20150734A1 (es) Inhibidores de glucosilceramida sintasa
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CR20140301A (es) Derivados de betulina
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
AR090928A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos
MY177250A (en) Novel nicotinamide derivative or salt thereof
EA201400247A1 (ru) Сельскохозяйственная и садоводческая фунгицидная композиция
AR065876A1 (es) Compuestos activos para 11 beta -hsd1
AR078463A1 (es) Composicion y metodo para controlar plagas de artropodos
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CY1117843T1 (el) Νεα παραγωγα θειενοπυριμιδινης, διεργασιες για την παρασκευη αυτων και θεραπευτικες χρησεις αυτων
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος
MX361458B (es) Compuestos de pirimido-piridazinona y uso de los mismos.
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112013010850A8 (pt) Composto de etinilfenilamidina ou sal do mesmo, método para produzir o mesmo e fungicida para uso agrícola e em horticultura
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4
BR112014004275A2 (pt) derivados de isoxazolina como compostos inseticidas
AR086113A1 (es) Isoxazolinas como agentes terapeuticos
MX348979B (es) Agente de control de enfermedades de las plantas.
CR20130476A (es) Derivados de pirazolidin-3-ona

Legal Events

Date Code Title Description
FG Grant, registration